May Health, a Menlo Park, CA-based developer of medical devices for polycystic ovary syndrome, has raised $11.7 million in a funding round led by Nexpring Health.
The round also saw participation from existing shareholders Sofinnova Partners, Bpifrance, and Trill Impact.
Read More:Nexthop AI Raises $500M in Series B Funding
The company plans to use the funds to complete its REBALANCE U.S. clinical trial, move forward with FDA marketing approval, and support the European launch of its Anavi™ System.
May Health’s Anavi System offers a one-time, in-office procedure aimed at restoring ovulation in women with PCOS-related infertility who do not respond to, cannot take, or choose not to use first-line treatments. The company is developing this new therapy in the U.S. through its REBALANCE pivotal IDE trial for eligible women, with the study designed to support FDA approval for marketing.
Nexpring Health is a global leader in assisted reproductive technology (ART), dedicated to advancing the future of fertility care.
PCOS affects 10–13% of women worldwide and is the most common endocrine disorder in women of reproductive age, making it a leading cause of female infertility. Women with PCOS-related infertility often have trouble getting pregnant because they cannot ovulate regularly or at all.
“For too long, women with PCOS-related infertility have had limited options to support family-building,” said Colby Holtshouse, President and CEO of May Health. “With the support of our investors we are making strong progress in enrolling the REBALANCE trial and preparing to bring the Anavi System to market in Europe and the U.S. We are excited to welcome Nexpring Health to our syndicate and celebrate the shared mission between our organizations.”
“May Health is filling an important gap in modern infertility care,” said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners. “By addressing the root causes of PCOS related infertility, the company is changing treatment options for millions of women worldwide. We are proud to support their world class team, making real progress in women’s healthcare.”
“At Nexpring Health, we see our role in ART as more than just creating products,” said Wil Boren, CEO of Nexpring Health. “It’s about improving fertility care for clinicians, lab embryologists, and, most importantly, the patients whose hopes rely on this work. May Health is doing the kind of work that can improve patient outcomes, expand treatment options, and advance the field, and we are proud to support them.”
About May Health
Founded in 2017, May Health is a medical device company focused on expanding treatment options for women with polycystic ovary syndrome (PCOS). The company is led by experienced medtech and women’s health executives with expertise in product development, clinical trials, regulatory strategy, and commercialization. Originally founded as Ziva Medical, May Health progressed through the Paris-based accelerator MD Start and previously operated as Ablacare before adopting its current name. Headquartered in Menlo Park, California, with roots in France, May Health is backed by lead investors Sofinnova Partners, Bpifrance, Trill Impact, and Nexpring Health.
About The REBALANCE Study
The REBALANCE Study is an ongoing, multicenter, randomized trial testing the safety and effectiveness of May Health’s technology for restoring ovulation in women with PCOS-related infertility. The study is recruiting women ages 18–40 who have PCOS and have not responded to, cannot take, or choose not to use first-line ovulation treatments.
Read More:PactFi Raises $25M in Series A Funding
